{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:12:58Z","timestamp":1794971578998,"version":"4.9.1"},"reference-count":63,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2018.00661","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:52:43Z","timestamp":1522803163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":99,"title":["Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age"],"prefix":"10.3389","volume":"9","author":[{"given":"Toine","family":"Mercier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Guldentops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial","volume":"60","author":"Aguado","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"B2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1128\/JCM.44.2.389-394.2006","article-title":"Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders","volume":"44","author":"Aubry","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/infdis\/155.5.1005","article-title":"Receptor-mediated clearance of Aspergillus galactomannan","volume":"155","author":"Bennett","year":"1987","journal-title":"J. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1128\/JCM.00750-11","article-title":"Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients","volume":"50","author":"Bergeron","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1086\/339324","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease","volume":"34","author":"Boutboul","year":"2002","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e90176","DOI":"10.1371\/journal.pone.0090176","article-title":"Voriconazole or Amphotericin B as Primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive Aspergillosis","volume":"9","author":"Chai","year":"2014","journal-title":"PLoS ONE"},{"key":"B8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1128\/JCM.02913-15","article-title":"Diagnostic performance of galactomannan antigen testing in cerebrospinal fluid","volume":"54","author":"Chong","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/cid\/cit393","article-title":"The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive Aspergillosis","volume":"57","author":"Fisher","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.patbio.2011.10.011","article-title":"Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis","volume":"60","author":"Hadrich","year":"2012","journal-title":"Pathol. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12879-015-1014-9","article-title":"Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis","volume":"15","author":"Han","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/cid\/civ103","article-title":"Invasive aspergillosis after kidney transplant: case-control study","volume":"60","author":"Heylen","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"B13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1086\/510535","article-title":"Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy","volume":"195","author":"Hope","year":"2007","journal-title":"J. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/tid.12301","article-title":"Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients","volume":"16","author":"Hoyo","year":"2014","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1128\/AAC.03023-15","article-title":"Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy","volume":"60","author":"Huurneman","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.cmi.2016.01.027","article-title":"Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients","volume":"22","author":"Imbert","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2017.05.007","article-title":"Clinical characteristics, radiologic findings, risk factors and outcomes of serum galactomannan-negative invasive pulmonary aspergillosis","author":"Jung","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/0255-0857.108717","article-title":"Variables affecting the performance of galactomannan assay in high-risk patients at a tertiary care centre in India","volume":"31","author":"Khanna","year":"2013","journal-title":"Indian J. Med. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3346\/jkms.2014.29.1.61","article-title":"Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea","volume":"29","author":"Kim","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00124","DOI":"10.1128\/AAC.00124-17","article-title":"In vivo biomarker analysis of the effects of intranasally dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus infection in immunocompromised mice","volume":"61","author":"Kimura","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1128\/JCM.02281-09","article-title":"Prognostic Features of galactomannan antigenemia in galactomannan-positive invasive Aspergillosis","volume":"48","author":"Koo","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1128\/JCM.42.1.435-438.2004","article-title":"Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients","volume":"42","author":"Kwak","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"B23","first-page":"148","article-title":"Assessment of Platelia Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis","volume":"40","author":"Lai","year":"2007","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"i19","DOI":"10.1093\/jac\/dkx030","article-title":"Early diagnosis of invasive mould infections and disease","volume":"72","author":"Lamoth","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1128\/IAI.62.12.5424-5433.1994","article-title":"Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus","volume":"62","author":"Latg\u00e9","year":"1994","journal-title":"Infect. Immun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"CD007394","DOI":"10.1002\/14651858.CD007394.pub2","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","volume":"2015","author":"Leeflang","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/ajt.13837","article-title":"Clinical presentation and determinants of mortality of invasive pulmonary Aspergillosis in kidney transplant recipients: a multinational cohort study","volume":"16","author":"L\u00f3pez-Medrano","year":"2016","journal-title":"Am. J. Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.24022","article-title":"Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients","volume":"115","author":"Maertens","year":"2009","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1086\/430826","article-title":"Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1473-3099(04)01045-X","article-title":"Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis","volume":"4","author":"Mennink-Kersten","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1086\/511080","article-title":"When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all","volume":"44","author":"Miceli","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/cid\/cit565","article-title":"Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive Aspergillosis","volume":"57","author":"Mikulska","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2017","journal-title":"J. Infect. Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0129022","DOI":"10.1371\/journal.pone.0129022","article-title":"Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis","volume":"10","author":"Neofytos","year":"2015","journal-title":"PLoS ONE"},{"key":"B36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/cid\/cir441","article-title":"Earlier response assessment in invasive Aspergillosis based on the kinetics of serum Aspergillus Galactomannan: proposal for a new definition","volume":"53","author":"Nou\u00e9r","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1093\/cid\/cis298","article-title":"Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis","volume":"54","author":"Nou\u00e9r","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1439-0507.2010.02009.x","article-title":"Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients","volume":"54","author":"Park","year":"2011","journal-title":"Mycoses"},{"key":"B39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jinf.2011.08.007","article-title":"Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value","volume":"63","author":"Park","year":"2011","journal-title":"J. Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group","volume":"46","author":"Pauw","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/mmy\/myv034","article-title":"Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1\u2013>3)-beta-D-glucan in experimental invasive pulmonary aspergillosis","volume":"53","author":"Petraitiene","year":"2015","journal-title":"Med. Mycol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1128\/AAC.45.3.857-869.2001","article-title":"Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: correlation with Galactomannan Antigenemia","volume":"45","author":"Petraitiene","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1128\/AAC.46.1.12-23.2002","article-title":"Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary Aspergillosis in persistently neutropenic rabbits: pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia","volume":"46","author":"Petraitiene","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1128\/AAC.02665-15","article-title":"Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary Aspergillosis","volume":"60","author":"Petraitis","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s15010-015-0849-8","article-title":"Evaluation of serum (1 \u2013> 3)-beta-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors","volume":"44","author":"Pini","year":"2016","journal-title":"Infection"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1016\/j.ijid.2011.09.011","article-title":"Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases\u2014the role of factors affecting assay performance","volume":"15","author":"Racil","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1128\/JCM.02969-15","article-title":"urine galactomannan-to-creatinine ratio for detection of invasive Aspergillosis in patients with hematological malignancies","volume":"54","author":"Reischies","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.diagmicrobio.2014.05.015","article-title":"Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?","volume":"80","author":"Russo","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1128\/JCM.43.7.3560-3563.2005","article-title":"Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodialysis","volume":"43","author":"Saleeby","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/003655400458749","article-title":"Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome","volume":"32","author":"Salonen","year":"2000","journal-title":"Scand. J. Infect. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and european organization for research and treatment of cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1469-0691.2005.01349.x","article-title":"Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis","volume":"12","author":"Sheppard","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"B54","first-page":"1851","article-title":"Galactomannan antigenemia for the diagnosis of invasive aspergillosis in neutropenic patients with hematological disorders","volume":"89","author":"Suankratay","year":"2006","journal-title":"J. Med. Assoc. Thail."},{"key":"B55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5603\/AIT.2014.0027","article-title":"Prognostic value of serum galactomannan in mixed ICU patients: a retrospective observational study","volume":"46","author":"Teering","year":"2014","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1007\/s00330-016-4717-4","article-title":"Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis","volume":"27","author":"Vehreschild","year":"2017","journal-title":"Eur. Radiol."},{"key":"B57","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1128\/JCM.38.10.3900-3901.2000","article-title":"Failure to detect circulating aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis","volume":"38","author":"Verweij","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s00253-015-7209-6","article-title":"Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis","volume":"100","author":"Vidal-Garc\u00eda","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1128\/CVI.00730-12","article-title":"Comparison of galactomannan enzyme immunoassay performance levels when testing serum and plasma samples","volume":"20","author":"White","year":"2013","journal-title":"Clin. Vaccine. Immunol. CVI"},{"key":"B61","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/cncr.22863","article-title":"Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer","volume":"110","author":"Woods","year":"2007","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/mmy\/myw043","article-title":"Blood Aspergillus RNA is a promising alternative biomarker for invasive aspergillosis","volume":"54","author":"Zhao","year":"2016","journal-title":"Med. Mycol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e43347","DOI":"10.1371\/journal.pone.0043347","article-title":"Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive Aspergillosis","volume":"7","author":"Zou","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2018.00661\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T20:37:04Z","timestamp":1604090224000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2018.00661\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":63,"alternative-id":["10.3389\/fmicb.2018.00661"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2018.00661","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"article-number":"661"}}